PT - JOURNAL ARTICLE AU - Homan, Edwin A. AU - Gilani, Ankit AU - Rubio-Navarro, Alfonso AU - Johnson, Maya AU - Cortada, Eric AU - Pereira de Lima, Renan AU - Stoll, Lisa AU - Lo, James C. TI - Complement 3a Receptor 1 on Macrophages and Kupffer cells is not required for the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease AID - 10.1101/2024.06.26.24309550 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.26.24309550 4099 - http://medrxiv.org/content/early/2024/06/28/2024.06.26.24309550.short 4100 - http://medrxiv.org/content/early/2024/06/28/2024.06.26.24309550.full AB - Together with obesity and type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global epidemic. Activation of the complement system and infiltration of macrophages has been linked to progression of metabolic liver disease. The role of complement receptors in macrophage activation and recruitment in MASLD remains poorly understood. In human and mouse, C3AR1 in the iver is expressed primarily in Kupffer cells, but is downregulated in humans with MASLD compared to obese controls. To test the role of complement 3a receptor (C3aR1) on macrophages and liver resident macrophages in MASLD, we generated mice deficient in C3aR1 on all macrophages (C3aR1-MφKO) or specifically in liver Kupffer cells (C3aR1-KpKO) and subjected them to a model of metabolic steatotic liver disease. We show that macrophages account for the vast majority of C3ar1 expression in the liver. Overall, C3aR1-MφKO and C3aR1-KpKO mice have similar body weight gain without significant alterations in glucose homeostasis, hepatic steatosis and fibrosis, compared to controls on a MASLD-inducing diet. This study demonstrates that C3aR1 deletion in macrophages or Kupffer cells, the predominant liver cell type expressing C3aR1, has no significant effect on liver steatosis, inflammation or fibrosis in a dietary MASLD model.Competing Interest StatementThe authors have declared no competing interest.Funding StatementE.A.H. was supported by NIH T32 5T32HL160520-02. A.G. was supported by was supported by ADA 9-22-PDFPM-01. R.P.L was supported by AHA 23DIVSUP1074485. L.S. was supported by AHA 908952 and an Ehrenkranz Young Scientist Award. J.C.L. was supported by NIH R01 DK121140, R01 DK121844, and R01 DK132879.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research performed under Weill Cornell / Memorial Sloan Kettering IACUC protocol #2015-0020.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be made available upon reasonable request.